A wobbly Biogen makes a surprise switch in the executive suite, triggering a renewed burst of M&A chatter
Right on the eve of releasing their Q2 numbers, Biogen $BIIB managed to surprise just about everyone with the news Tuesday night that CFO Jeff …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
